Absorbable Stent Approved for Coronary Heart Disease Treatment

Coronary heart disease kills about 370,000 Americans each year, according to the National Heart, Lung, and Blood Institute.

The U.S. Food and Drug Administration on July 5 approved the first fully absorbable stent to treat coronary artery disease. The Absorb GT1 Bioresorbable Vascular Scaffold System releases the drug everolimus to limit the growth of scar tissue and is gradually absorbed by the body in approximately three years, the agency announced. The Absorb GT1 BVS is manufactured by Abbott Vascular in Santa Clara, Calif.

"The FDA's approval of the Absorb GT1 BVS offers a new treatment option for individuals who are candidates for angioplasty but would prefer an absorbable device rather than a permanent metallic coronary stent," said Dr. Bram Zuckerman, M.D., director of the division of cardiovascular devices at FDA's Center for Devices and Radiological Health.

Coronary heart disease kills about 370,000 Americans each year, according to the National Heart, Lung, and Blood Institute.

The Absorb GT1 BVS is manufactured from a biodegradable polymer called poly(L-lactide), which resembles materials used in other types of absorbable medical devices, such as sutures. After the device is absorbed, only four small platinum markers are embedded in the walls of the artery, which help cardiologists identify where the Absorb GT1 BVS was originally placed.

In approving the product, FDA evaluated data from a randomized trial of 2,008 patients. After a year, the Absorb GT1 BVS group showed a major cardiac adverse event rate of 7.8 percent, which was clinically comparable to the rate of 6.1 percent observed in the control group. The rate of blood clots forming within the devices was 1.54 percent for the Absorb GT1 BVS and 0.74 percent rate for the control.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2022

    June 2022

    Featuring:

    • SAFETY CULTURE
      Corporate Safety Culture Is Workplace Culture
    • HEAT STRESS
      Keeping Workers Safe from Heat-Related Illnesses & Injuries
    • EMPLOYEE HEALTH SCREENING
      Should Employers Consider Oral Fluid Drug Testing?
    • PPE FOR WOMEN
      Addressing Physical Differences
    View This Issue